ES2069836T3 - Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1). - Google Patents

Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).

Info

Publication number
ES2069836T3
ES2069836T3 ES91311583T ES91311583T ES2069836T3 ES 2069836 T3 ES2069836 T3 ES 2069836T3 ES 91311583 T ES91311583 T ES 91311583T ES 91311583 T ES91311583 T ES 91311583T ES 2069836 T3 ES2069836 T3 ES 2069836T3
Authority
ES
Spain
Prior art keywords
indol
dimethylamine
ethyl
methyl
methanosulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91311583T
Other languages
English (en)
Inventor
Joanne Craig
Derek Leslie Crookes
Stephen John Skittrall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2069836T3 publication Critical patent/ES2069836T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

SE REVELA UNA SAL DE SULFATO 3-(2-DIMETILAMINO)ETIL)-N-METIL-1H-INDOL-5 -METANOSULFONAMIDA (2:1) Y SOLVATADOS FARMACEUTICAMENTE ACEPTABLE DE LO MISMO. EL COMPUESTO ES DE UTILIDAD EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS, PARTICULARMENTE PARA FORMULACIONES INTRANASALES, PARA UTILIZAR EN EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON DOLOR DE CABEZA, EN PARTICULAR MIGRAÑA.
ES91311583T 1990-12-12 1991-12-12 Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1). Expired - Lifetime ES2069836T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (1)

Publication Number Publication Date
ES2069836T3 true ES2069836T3 (es) 1995-05-16

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91311583T Expired - Lifetime ES2069836T3 (es) 1990-12-12 1991-12-12 Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).

Country Status (36)

Country Link
US (2) US5554639A (es)
EP (1) EP0490689B1 (es)
JP (1) JP2994037B2 (es)
KR (1) KR100211479B1 (es)
CN (2) CN1030890C (es)
AP (1) AP230A (es)
AT (1) ATE119881T1 (es)
AU (1) AU650706B2 (es)
BE (1) BE1005085A3 (es)
CA (1) CA2098302C (es)
CH (1) CH684192A5 (es)
CY (1) CY2005A (es)
CZ (1) CZ281931B6 (es)
DE (1) DE69108200T2 (es)
DK (1) DK0490689T3 (es)
EG (1) EG20219A (es)
ES (1) ES2069836T3 (es)
FR (1) FR2670487B1 (es)
GB (2) GB9026998D0 (es)
GR (1) GR3015430T3 (es)
HK (1) HK82697A (es)
HU (1) HU211937A9 (es)
IE (1) IE62894B1 (es)
IL (1) IL100330A (es)
IS (1) IS1706B (es)
IT (1) IT1252868B (es)
MX (1) MX9102501A (es)
MY (1) MY109265A (es)
NL (1) NL9102071A (es)
NZ (1) NZ240942A (es)
PT (1) PT99757B (es)
RU (1) RU2108328C1 (es)
TW (2) TW205035B (es)
WO (1) WO1992010477A1 (es)
YU (1) YU48926B (es)
ZA (1) ZA919750B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318212T2 (de) * 1992-06-05 1998-11-19 Merck Sharp & Dohme Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
CN102046621B (zh) 2008-05-27 2014-11-12 生物区科学管理控股有限公司 抗病毒盐
US8618157B2 (en) * 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10494405B2 (en) 2015-05-15 2019-12-03 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CA3079848A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2021173936A1 (en) * 2020-02-27 2021-09-02 Biohaven Pharmaceutical Holding Company Ltd. Oral fast-dispersing dosage form of rimegepant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
BE1005085A3 (fr) 1993-04-13
EG20219A (en) 1997-11-30
CZ114093A3 (en) 1994-02-16
ZA919750B (en) 1992-10-28
MX9102501A (es) 1992-09-01
GR3015430T3 (en) 1995-06-30
DK0490689T3 (da) 1995-05-22
DE69108200D1 (de) 1995-04-20
JP2994037B2 (ja) 1999-12-27
IE914317A1 (en) 1992-06-17
WO1992010477A1 (en) 1992-06-25
IL100330A (en) 1996-06-18
IL100330A0 (en) 1992-09-06
US5554639A (en) 1996-09-10
EP0490689B1 (en) 1995-03-15
CY2005A (en) 1997-12-05
ATE119881T1 (de) 1995-04-15
TW205035B (es) 1993-05-01
AU650706B2 (en) 1994-06-30
MY109265A (en) 1996-12-31
US5705520A (en) 1998-01-06
DE69108200T2 (de) 1995-07-20
CN1050831C (zh) 2000-03-29
PT99757A (pt) 1992-12-31
CA2098302C (en) 2001-10-16
AP9100339A0 (en) 1992-01-31
HK82697A (en) 1997-06-27
GB2251614A (en) 1992-07-15
CH684192A5 (fr) 1994-07-29
ITRM910922A0 (it) 1991-12-11
CN1128259A (zh) 1996-08-07
TW300886B (es) 1997-03-21
ITRM910922A1 (it) 1993-06-11
CZ281931B6 (cs) 1997-04-16
NZ240942A (en) 1994-03-25
AP230A (en) 1993-01-27
FR2670487B1 (fr) 1993-08-20
CN1030890C (zh) 1996-02-07
IT1252868B (it) 1995-06-28
PT99757B (pt) 1999-05-31
GB2251614B (en) 1994-12-14
AU9072091A (en) 1992-07-08
CN1063099A (zh) 1992-07-29
IE62894B1 (en) 1995-03-08
NL9102071A (nl) 1992-07-01
GB9126297D0 (en) 1992-02-12
GB9026998D0 (en) 1991-01-30
KR100211479B1 (ko) 1999-08-02
HU211937A9 (en) 1996-01-29
JPH06503560A (ja) 1994-04-21
FR2670487A1 (fr) 1992-06-19
YU48926B (sh) 2002-12-10
IS3790A7 (is) 1992-06-13
EP0490689A1 (en) 1992-06-17
CA2098302A1 (en) 1992-06-13
RU2108328C1 (ru) 1998-04-10
YU191491A (sh) 1994-04-05
IS1706B (is) 1998-12-10

Similar Documents

Publication Publication Date Title
ES2069836T3 (es) Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).
RU93053493A (ru) Сульфатная соль (2:1)-3-[2-(диметиламино)этил]-n-метил-1н-индол-5-метансульфонамида и ее фармацевтически приемлемые сольваты, способ их получения, фармацевтические композиции на их основе, их применение в терапии, способ лечения головной боли
AU4005985A (en) 2-oxindole-1-carboxamide derivatives
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
ES2117015T3 (es) Composiciones que contienen sumatriptan.
NO963053L (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
NO932670L (no) Blandinger
PH17786A (en) New methyl substituted 4-methoxy-pyridine-n-oxides to be used as intermediate in the preparation of the new intermediate
PT91126A (pt) Processo para a preparacao de derivados de (1-hidroxi-2-piperidinil-alquil)-2- indolonas, 2-quinoleinonas, benzo {b}-2-azepinonas, 2-benzimidazolonas e 2- -quinazolinonas e de composicoes farmaceuticas que os contem
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
LTIP1518A (en) Novel tetrazole derivatives, process for the preparing thereof and pharmaceutical composition comprising the same
AU1876792A (en) Pharmacologically enhanced formulations
DE3767114D1 (de) Stabilisierte arzneimittel.
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
MX9301721A (es) Derivados, composiciones de carbinol de bis-arilo sin puente, y metodos de uso.
ES2082515T3 (es) Composiciones de aseo.
NZ246598A (en) Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds
SK60595A3 (en) Pharmaceutical agents containing gemfibrozil
ECSP941088A (es) Composiciones
AU2845489A (en) Process for preparing hydroxyakylating agents, the agents so obtained, and their use
DE3465594D1 (en) Tropone derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
YU12191A (sh) Kristalni hidrohlorid novog beta-laktamskog antibiotika i postupak za njegovo dobijanje

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490689

Country of ref document: ES